Type 2 Diabetes

Results from the largest and longest trial of orforglipron to date have displayed the drug’s efficacy in reducing all-cause cardiovascular death and MACE incidence.

Although the approval does not permit entrance into the market, this decision marks an important step to more universally accessible GLP-1 RAs.

Catch up on FDA decisions, new GLP-1 agonists, and more.

This episode covers the March 26th approval of Awiqli for T2D, highlighting its high concentration and once-weekly administration.

This episode discusses the recently released algorithm for T2D from the American Association of Clinical Endocrinology.

Hosts break down the latest updates in mineralocorticoid receptor agonists, including the SPIRIT-HF trial and announcements from the finerenone program.

Laurel Messer, PhD, RN, joins the show to provide insight into the latest updates from Tandem Diabetes Care.

Results of the MOMENTUM trial suggest the prevalence of hypercortisolism in resistant hypertension could be greater than previous estimates have indicated.

A subgroup analysis of VESALIUS-CV suggests evolocumab could have a role in prevention of primary events in some high-risk patients.

The indication makes insulin icodec the first new class of basal insulin to reach US patients in more than 2 decades.

National cohort study finds semaglutide tied to reduced depression, anxiety, and self-harm risk in patients with diabetes and comorbid mental illness.

This episode features discussion around 3 recent announcements from Novo Nordisk, Eli Lilly, and Structure Therapeutics.

The first-in-class GIP, GLP-1 and glucagon triple hormone receptor agonist delivered superior A1C reduction and weight loss at 40 weeks in people with type 2 diabetes.

ATTD 2026 reveals AI “digital twins,” next-gen closed-loop pumps, and sensors that boost time-in-range and ease diabetes management.

The MiniMed Flex is a discreet, smartphone-controlled insulin pump that is roughly the size of 2 stacked insulin vials.

Tozzi and Wallach discuss ways to omit artificial sweeteners and added sugars from children’s diets and minimize risk for T2D and MASLD later in life.

Diabetes Dialogue cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, cover the recently published trial results and what they mean for Eli Lilly’s newest GLP-1 molecule.

Catch up with FDA decisions, key trial results, podcast updates, and more.

Isaacs and Bellini discuss recent updates on Eli Lilly's orforglipron and retatrutide and Novo Nordisk's UBT251, along with other recent GLP-1 news.

Parent company Eli Lilly has released full data from ACHIEVE-3, indicating superior weight loss and A1C reductions with orforglipron 12 mg and 36 mg.

The list price of all 3 semaglutide drugs will be lowered to $675, marking a reduction of roughly 50% and 35% for Wegovy and Ozempic, respectively.

Diabetes Dialogue cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss the Portal Pump's recent Breakthrough Designation from the FDA.

1 year into real-world use, 4 clinicians discuss how semaglutide is transforming the endocrinology, nephrology, and cardiology landscape.

Diabetes Dialogue Cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, cover the patient awareness motivation behind Novo Nordisk’s recent announcement.

Cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss the controversy surrounding Hims and Hers and the risks of compounding GLP-1 formulas.